Alexis Leonard
Overview
Explore the profile of Alexis Leonard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collins G, Levine D, Leonard A, Sharma A, Johnson L
Front Oncol
. 2025 Feb;
15:1535851.
PMID: 40018407
People with severe sickle cell disease (SCD) are now presented with increasing access to curative-intent therapies including allogeneic hematopoietic stem cell transplantation (HCT) and gene therapy (GT). These high-risk, high-reward...
2.
Demirci S, Zeng J, Palchaudhuri R, Wu C, Abraham D, Hayal T, et al.
Cell Stem Cell
. 2024 Dec;
32(2):209-226.e8.
PMID: 39642886
Editing the +58 region of the BCL11A erythroid enhancer has shown promise in treating β-globin disorders. To address variations in fetal hemoglobin (HbF) response, we investigated editing both +58 and ...
3.
Ruhl A, Shalhoub R, Jeffries N, Limerick E, Leonard A, Barochia A, et al.
Ann Am Thorac Soc
. 2024 Aug;
21(10):1398-1406.
PMID: 39189784
Sickle cell disease (SCD) is a monogenetic condition with recurring vasoocclusive events causing lifelong pulmonary morbidity and mortality. There is increasing access to curative therapies, such as hematopoietic cell transplant...
4.
Persaud Y, Leonard A, Rai P
Expert Opin Emerg Drugs
. 2024 Jul;
29(4):327-346.
PMID: 38988318
Introduction: Since its discovery in the early 1900s, sickle cell disease (SCD) has contributed significantly to the scientific understanding of hemoglobin and hemoglobinopathies. Despite this, now almost a century later,...
5.
Demirci S, Khan M, Hinojosa G, Le A, Leonard A, Essawi K, et al.
Cytotherapy
. 2024 Mar;
26(6):641-648.
PMID: 38506770
Ex vivo resting culture is a standard procedure following genome editing in hematopoietic stem and progenitor cells (HSPCs). However, prolonged culture may critically affect cell viability and stem cell function....
6.
Leonard A, Weiss M
Curr Opin Hematol
. 2024 Feb;
31(3):104-114.
PMID: 38359264
Purpose Of Review: Gene therapy for sickle cell disease (SCD) is advancing rapidly, with two transformative products recently approved by the US Food and Drug Administration and numerous others under...
7.
8.
Leonard A, Tisdale J
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):542-547.
PMID: 38066927
Sickle cell disease (SCD) is potentially curable after allogeneic hematopoietic stem cell transplantation (HSCT) or autologous HSCT after ex vivo genetic modification. Autologous HSCT with gene therapy has the potential...
9.
Inam Z, Tisdale J, Leonard A
Expert Rev Hematol
. 2023 Oct;
16(11):879-903.
PMID: 37800996
Introduction: Hematopoietic stem cell transplant (HSCT) is the only readily available curative option for sickle cell disease (SCD). Cure rates following human leukocyte antigen (HLA)-matched related donor HSCT with myeloablative...
10.
Martin O, Darbari D, Margulies S, Nickel R, Leonard A, Speller-Brown B, et al.
Front Med (Lausanne)
. 2023 Mar;
10:987194.
PMID: 36873869
Background: COVID-19 was declared a global pandemic in March 2020. Early reports were primarily in adults, and sickle cell disease (SCD) was classified as a risk factor for severe COVID-19...